학술논문
Readmissions, Postdischarge Mortality, and Sustained Recovery Among Patients Admitted to Hospital With Coronavirus Disease 2019 (COVID-19).
Document Type
Article
Author
Source
Subject
*CAUSES of death
*RESEARCH
*INTENSIVE care units
*PATIENT aftercare
*COVID-19
*NOSOLOGY
*CONFIDENCE intervals
*CONVALESCENCE
*DEXAMETHASONE
*PATIENT readmissions
*ANTIVIRAL agents
*HEALTH status indicators
*DISEASE incidence
*TREATMENT effectiveness
*SEVERITY of illness index
*HOSPITAL mortality
*CATASTROPHIC illness
*DESCRIPTIVE statistics
*PUBLIC hospitals
*QUESTIONNAIRES
*RESEARCH funding
*DATA analysis software
*DISCHARGE planning
*COMORBIDITY
*PROPORTIONAL hazards models
*LONGITUDINAL method
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
1058-4838
Abstract
Background Many interventional in-patient coronavirus disease 2019 (COVID-19) trials assess primary outcomes through day 28 post-randomization. Since a proportion of patients experience protracted disease or relapse, such follow-up period may not fully capture the course of the disease, even when randomization occurs a few days after hospitalization. Methods Among adults hospitalized with COVID-19 in eastern Denmark from 18 March 2020–12 January 2021 we assessed all-cause mortality, recovery, and sustained recovery 90 days after admission, and readmission and all-cause mortality 90 days after discharge. Recovery was defined as hospital discharge and sustained recovery as recovery and alive without readmissions for 14 consecutive days. Results Among 3386 patients included in the study, 2796 (82.6%) reached recovery and 2600 (77.0%) achieved sustained recovery. Of those discharged from hospital, 556 (19.9%) were readmitted and 289 (10.3%) died. Overall, the median time to recovery was 6 days (interquartile range [IQR]: 3–10), and 19 days (IQR: 11–33) among patients in intensive care in the first 2 days of admission. Conclusions Postdischarge readmission and mortality rates were substantial. Therefore, sustained recovery should be favored to recovery outcomes in clinical COVID-19 trials. A 28-day follow-up period may be too short for the critically ill. [ABSTRACT FROM AUTHOR]